ilomastat has been researched along with Centriacinar Emphysema in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Ding, K; Ge, A; Gong, LK; Jiang, Y; Li, J; Ma, D; Ren, J; Wang, R; Xu, Y; Ye, Q | 1 |
| Barr, PJ; Cantwell, JS; Fink, JB; Kim, KM; Kobayashi, D; Pemberton, PA; Shapiro, SD; Sundin, DJ | 1 |
2 other study(ies) available for ilomastat and Centriacinar Emphysema
| Article | Year |
|---|---|
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.
Topics: Animals; Cricetinae; Isoenzymes; Keto Acids; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mesocricetus; Models, Molecular; Pancreatic Elastase; Pulmonary Emphysema; Structure-Activity Relationship; Swine | 2006 |
An inhaled matrix metalloprotease inhibitor prevents cigarette smoke-induced emphysema in the mouse.
Topics: Administration, Inhalation; Animals; Female; Hydroxamic Acids; Indoles; Mice; Mice, Inbred Strains; Nebulizers and Vaporizers; Nicotiana; Pulmonary Emphysema; Smoke | 2005 |